NBIX

NBIX

USD

Neurocrine Biosciences Inc. Common Stock

$143.190+1.220 (0.859%)

Echtzeitkurs

Healthcare
Drug Manufacturers - Specialty & Generic
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$141.970

Hoch

$143.870

Tief

$140.820

Volumen

0.26M

Unternehmensfundamentaldaten

Marktkapitalisierung

14.3B

Branche

Drug Manufacturers - Specialty & Generic

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.86M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $84.23Aktuell $143.190Hoch $154.61

Ähnliche Nachrichten

Analyst Upgrades

Truist Securities Reiterates Buy on Neurocrine Biosciences, Raises Price Target to $172

Truist Securities analyst Danielle Brill reiterates Neurocrine Biosciences with a Buy and raises the price target from $165 to $172.

Mehr anzeigen
Truist Securities Reiterates Buy on Neurocrine Biosciences, Raises Price Target to $172
Analyst Upgrades

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $164

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences with a Buy and raises the price target from $160 to $164.

Mehr anzeigen
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $164
Analyst Upgrades

Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $183

Stifel analyst Paul Matteis maintains Neurocrine Biosciences with a Buy and raises the price target from $174 to $183.

Mehr anzeigen
Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $183
Analyst Upgrades

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $160

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences with a Outperform and raises the price target from $156 to $160.

Mehr anzeigen
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $160
Analyst Upgrades

Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $179

Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences with a Overweight and raises the price target from $175 to $179.

Mehr anzeigen
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $179
Analyst Upgrades

Needham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $184

Needham analyst Ami Fadia maintains Neurocrine Biosciences with a Buy and raises the price target from $170 to $184.

Analyst Upgrades

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $195

UBS analyst Ashwani Verma maintains Neurocrine Biosciences with a Buy and raises the price target from $188 to $195.